Jin Medical International Ltd. (NASDAQ: ZJYL) experienced a dramatic premarket surge on Monday, with shares trading at $4.3425, up 101.98% from Friday's close of $2.15. The stock, which hovered around $4.30 ahead of the opening bell, saw trading volume exceeding 9 million shares—more than five times the company's reported free float of 1.673 million shares.
The sharp price movement reflects a fundamental reset in the company's capital structure following its July acquisition. Jin Medical now reports 78.43 million shares outstanding, nearly ten times the 7.83 million shares recorded in March. At the premarket price, this equates to an equity value of approximately $340.6 million, a stark contrast to the $16.8 million market capitalization still displayed on some quote pages, which was based on the old share count and Friday's closing price.
The acquisition involved the issuance of 64.19 million shares for the deal and an additional 6.42 million shares for advisers, collectively representing 90% of the post-transaction share total. The purchase price was set at $1.641 per share, making Monday's premarket quote 164.6% higher. Analysts have not yet established coverage, with no ratings or price targets available from FactSet.
The stock's ascent began in the latter part of last week, rising 11.4% during regular sessions from Monday's close of $1.93 to Friday's $2.15, after touching a low of $1.53 on Thursday. The majority of gains occurred in after-hours and premarket trading, suggesting limited participation from retail investors during regular hours.
Jin Medical's operational performance has been mixed. Unaudited revenue for the first half declined 9.7% to $8.9 million, though gross margin improved to 26.9% from 24.3%. The company posted a minor net loss of $0.2 million, compared to a slight profit in the prior year period. CEO Erqi Wang attributed the decline to "temporary foreign-exchange pressure" related to its top Japanese client, while highlighting $30.1 million in cash and investments as evidence of a "solid financial position."
Revenue from wheelchairs slipped 1.4% to $7.1 million, while component sales grew 9.9% to $1.1 million. Other-product revenue plummeted 59.1% after the company discontinued electric-scooter sales due to failed qualifications. Research and development spending increased 33.4% to $0.9 million.
The capital structure shift is the primary driver of the valuation reset. As of July 28, only 1.673 million Class A shares were non-restricted, representing a mere 2.13% of total shares. The limited free float has created extreme volatility, with premarket volume of 9.07 million shares dwarfing the available supply.
Investors are now focused on Monday's regular session to see if the price holds with broader participation. Risks remain elevated due to the thin float, which could lead to swift reversals. Additionally, the Tongsheng deal utilizes VIE agreements rather than direct share ownership, and a single customer group accounts for 73.3% of revenue. Each Class B share carries 800 votes, concentrating control.
The post-transaction equity value at Friday's close was an estimated $168.6 million, based on reporter calculations. At Monday's premarket price, that figure rises to $340.6 million, highlighting the disconnect between outdated market data and the company's current structure.
